| February 2001 |
Perseus Proteomics is established in Bunkyo-ku, Tokyo. |
| October 2002 |
A number of anti-nuclear receptor monoclonal antibodies are released as research reagents. |
| April 2003 |
The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by the New Energy and Industrial Technology Development Organization (NEDO) of the Ministry of Economy, Trade and Industry. |
| July 2003 |
The company relocates head office to Shibuya-ku, Tokyo. |
| August 2004 |
The company signs a distributorship agreement with R&D Systems Inc. for the distribution of its research reagents in the United States and initiates global sales. |
| September 2004 |
The company relocates head office to Meguro-ku, Tokyo. |
| September 2005 |
The complete lineup of antibodies that target all 48 nuclear receptors is presented. |
| September 2006 |
The company signs an agreement with Chugai Pharmaceutical Co., Ltd. for the transfer of right for the therapeutic use of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001).” |
| September 2008 |
The research reagent “PTX3 ELISA kit” is released. |
| November 2008 |
A phase I clinical trial of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001)” begins in the United States. |
| January 2009 |
Through shareholder allocation, FUJIFILM Corporation increases its capital in Perseus Proteomics by acquiring 76.68% of the issued shares to become the parent company. |
| January 2011 |
A radioisotope (RI)-labeled antibody (PPMX-T002), an anticancer drug, is licensed to FUJIFILM Corporation. |
| December 2014 |
A drug for the treatment of adult T-cell leukemia based on an anti-transferrin receptor antibody (PPMX-T003) is selected by the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) program of the Japan Science and Technology Agency (JST) for the practical application development (drug development) division. |
| September 2015 |
Antibody Drug Conjugate (PPMX-T004) is licensed to FUJIFILM Corporation. |
| January 2016 |
A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in the United States. |
| March 2018 |
After allocation of new shares to a third party, FUJIFILM Corporation reduces its percentage of shares of the Company to 48.62% and becomes an "other associated company". |
| January 2019 |
The company opens the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, for the maintenance and development of phage display technologies and the promotion of research and development of antibody drugs. |
| November 2019 |
A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) as an anticancer drug begins in Japan. |
| April 2020 |
A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in Japan. |
| June 2021 |
Shares of the Company are listed on Mothers Market, TSE |
| March 2022 |
Research and development on ANKL (PPMX-T003) is adopted as AMED Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation. |
| March 2022 |
License Agreement for PPMX-T002 and License & Knowhow Agreement for PPMX-T004 between FUJIFILM are terminated. |
| April 2022 |
The listed market transitions from Mother Market to Growth Market, TSE due to market segmentation restructuring of TSE. |
| September 2022 |
FUJIFILM Corporation is no longer "other associated company" due to reduction of its percentage of shares of the Company to 16.48%. |
| March 2023 |
Clinical Trial Notification of Investigator-led Phase I/II Clinical Trial for ANKL is submitted and approved.(PPMX-T003) |
| July 2023 |
The company relocates head office to Chuo-ku, Tokyo. |